Comparison of Methotrexate vs Placebo in Steroid-Refractory Ulcerative Colitis (METEOR)
Recruitment status was Recruiting
- PHASE: II
- TYPE OF STUDY : With direct benefit
- DESCRIPTIVE: Multicenter, randomized, double-blind study
- INCLUSION CRITERIA: Steroid-dependent ulcerative colitis
- OBJECTIVES: To show superiority of methotrexate vs placebo in inducing steroid-free remission in steroid-dependent ulcerative colitis
- STUDY TREATMENTS: Methotrexate 1 intramuscular injection (25 mg) per week Placebo 1 intramuscular injection per week
- NUMBERS OF PATIENTS: 55 patients in each group, i.e. a total of 110 patients
- INCLUSION PERIOD: 24 months
- STUDY DURATION: 36 months
- EVALUATION CRITERIA: Remission without steroids within at 16 and 24 weeks of treatment.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Controlled, Randomised, Double-Blind, Multicenter Study, Comparing Methotrexate vs Placebo in Steroid-Refractory Ulcerative Colitis|
|Study Start Date:||September 2007|
|Estimated Primary Completion Date:||November 2010 (Final data collection date for primary outcome measure)|
|Active Comparator: 1||
one methotrexate 25 mg intramuscular per week
|Placebo Comparator: 2||
one intramuscular injection per week
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that slightly reduces life expectancy, strongly reduces its quality and can lead to serious complications such as acute colitis, dysplasia and colon cancer. About 40'000 patients are affected in France Among them, 15% suffer from a chronic active form that often leads to an extended steroid therapy, and its known side effects. Azathioprine has already proven its efficacy in this indication but brings a lasting remission without steroid in only 41% of the patients (1-4). What are the medications available for the patients who failed in maintaining a remission with azathioprine ? Cyclosporin is designed for severe or steroid-resistant forms. (5). The results of two recent studies have showed that infliximab is more efficacious than placebo in active UC (6, 7). Infliximab is expensive, its efficacy in steroid-dependent UC has not been specifically tested yet, and its tolerance on the long term remains uncertain. Methotrexate proved its efficacy in Crohn's disease with an intramuscular dose of 25mg/week (8). In UC a controlled trial has been negative with an oral dose of 12.5mg/week (9). Another study compared mercaptopurine, methotrexate (15mg/week) and 5-aminosalicylate in 72 steroid-dependent patients with CD or UC (10). The remission rates obtained were 58% after 30 weeks with methotrexate (not significantly different from 5-ASA) and 14% after 106 weeks (not significantly different from 5-ASA). Few data are available on the efficacy of methotrexate in UC, at a dose which is active in Crohn's disease (25mg intramuscular/week). Several uncontrolled series have been published, including 91 patients whose remission failed under azathioprine.
Methotrexate is cheap and its patent has fallen in the public domain. Only institutional research will be able to finance a study in this new indication.
This is a prospective, controlled, randomized, double-blind study of methotrexate with an intramuscular dose of 25mg/week vs placebo in patients with steroid-dependent UC.
This multicenter study will take place under the aegis of the Therapeutic Study Group for Inflammatory Digestive Diseases (G.E.T.A.I.D.) and with the help of the gastroenterologists network of the CIC. The issue of this study is important. If the hypothesis is borne out, a cheap, efficacious medication will be available for chronic active UC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00498589
|Contact: Franck Carbonnel, Pr||00 33 3 81 66 82 firstname.lastname@example.org|
|Centre Hospitalier Universitaire de Besançon||Recruiting|
|Besançon, France, 25000|
|Contact: Franck Carbonnel, Pr 0391219312 ext 0033 email@example.com|
|Principal Investigator:||Franck Carbonnel||CHU Besançon|